(NASDAQ: NKTR) Nektar Therapeutics's forecast annual revenue growth rate of -11.16% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.3%.
Nektar Therapeutics's revenue in 2024 is $93,157,000.On average, 6 Wall Street analysts forecast NKTR's revenue for 2024 to be $14,329,298,884, with the lowest NKTR revenue forecast at $10,032,331,606, and the highest NKTR revenue forecast at $15,736,954,660. On average, 6 Wall Street analysts forecast NKTR's revenue for 2025 to be $12,012,106,402, with the lowest NKTR revenue forecast at $4,215,420,069, and the highest NKTR revenue forecast at $16,143,770,308.
In 2026, NKTR is forecast to generate $12,490,713,048 in revenue, with the lowest revenue forecast at $4,344,275,704 and the highest revenue forecast at $17,986,405,893.